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STATE-OF-THE-ART REVIEWTranscatheter Therapies for
the Treatment of Valvular and
Paravalvular Regurgitation in Acquired
and Congenital Valvular Heart Disease
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MaTranscatheter therapies in structural heart disease have evolved tremendously over the past 15 years. Since the intro-
duction of the ﬁrst balloon-expandable valves for stenotic lesions with implantation in the pulmonic position in 2000,
treatment for valvular heart disease in the outﬂow position has become more reﬁned, with newer-generation devices,
alternative techniques, and novel access approaches. Recent efforts into the inﬂow position and regurgitant lesions, with
transcatheter repair and replacement technologies, have expanded our potential to treat a broader, more heterogeneous
patient population. The evolution of multimodality imaging has paralleled these developments. Three- and 4-dimensional
visualization and concomitant use of novel technologies, such as fusion imaging, have supported technical growth, from
pre-procedural planning and intraprocedural guidance, to assessment of acute results and follow-up. A multimodality
approach has allowed operators to overcome many limitations of each modality and facilitated integration of a multi-
disciplinary team for treatment of this complex patient population. (J Am Coll Cardiol 2015;66:169–83)
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in incidence and prevalence of VHD. Advancements
in valve surgery and, more recently, in transcatheter
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ABBR EV I A T I ON S
AND ACRONYMS
AR = aortic regurgitation
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
CTA = computed tomography
angiography
FIM = ﬁrst-in-man
LV = left ventricle/ventricular
MR = mitral regurgitation
OR = odds ratio
PA = pulmonary artery
PAR = para-annular ring
regurgitation
PR = pulmonary regurgitation
PVL = paravalvular leak
RV = right ventricle/ventricular
RVOT = right ventricular
outﬂow tract
TA = transapical access
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
THV = transcatheter heart
valve
TMVR = transcatheter mitral
valve replacement
TPVR = transcatheter
pulmonary valve replacement
TR = tricuspid regurgitation
VARC = Valvular Associate
Research Consortium
VHD = valve heart disease
ViR = valve-in-ring
ViV = valve-in-valve
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170focused on examining current transcatheter
therapies for acquired and congenital val-
vular regurgitation, as well as for regurgitant
lesions after valve replacement or repair
(Central Illustration).
CLINICAL IMPLICATIONS OF
VALVULAR REGURGITATION
OUTFLOW VALVES. Aortic regurgitation
(AR) may develop with native valves or in
patients who have undergone previous sur-
gical or transcatheter valve interventions.
Transvalvular AR results from mechanical
leaﬂet malfunction or structural degenera-
tion following aortic valve replacement,
repair, or a valve-sparing procedure. Howev-
er, a paravalvular leak (PVL) is an abnormal
communication between the sewing ring of a
surgical prosthesis or sealing skirt of trans-
catheter prosthesis and the native leaﬂets.
Although the true incidence of aortic PVLs
following surgery is unknown, rates as high
as 11% have been reported (1,2). PVL is more
common following transcatheter aortic valve
replacement (TAVR), with rates as high as
85%, but the pooled estimate of residual
moderate or severe PVL is 7.4% (3). Predictors
of PVL include calcium burden and location,
valve undersizing or underexpansion, and
depth of implantation (4). AR leads to left
ventricular (LV) volume overload, ventricular
dilation, and failure (5). The clinical presen-
tation of PVL may be similar to native AR;
however, prosthetic dysfunction or PVL may
also cause intravascular hemolysis.
Pulmonary regurgitation (PR) is commonly
seen in patients with congenital heart dis-ease, particularly with a previous repaired tetralogy of
Fallot or signiﬁcant pulmonary valve stenosis for
which balloon or open valvuloplasty has been per-
formed (6). Surgical repair may involve a transannular
patch and/or resection of the pulmonary valve leaf-
lets. Patients with a history of pulmonary valve
replacement using either a biological conduit (i.e.,
homograft) or bioprosthetic tissue valve as part of the
original repair or a subsequent surgery are also at risk
for conduit valve dysfunction over time (7). Right
ventricular (RV) volume overload resulting from
chronic PR eventually causes RV dilation, progressive
systolic and diastolic dysfunction, and tricuspid
regurgitation (TR) that are due to annular dilation.
This can result in exercise intolerance, heart failure,
arrhythmias, and risk for sudden cardiac death (8). RVenlargement may also lead to adverse RV/LV interac-
tion, resulting in dysfunction (9). Timely consider-
ation of pulmonary valve replacement, together with
other interventions as needed for any potential ab-
normalities of RV afterload (e.g., central or peripheral
pulmonary artery [PA] stenosis, pulmonary arterial
hypertension), is integral in optimizing long-term
outcomes (10).
INFLOW VALVES. Native mitral regurgitation (MR) or
MR after mitral valve replacement or mitral valve
repair is not uncommon. The incidence of prosthetic
regurgitation depends on the type of prosthesis either
bioprosthetic or mechanical. Like aortic PVLs, the
true incidence of mitral PVLs is unknown; however,
rates as high as 32% have been reported (11). Volume
overload from MR induces progressive unfavorable
remodeling of the LV and left atrium. At later stages,
patients develop pulmonary hypertension, conges-
tive heart failure, and atrial ﬁbrillation (12). Hemo-
dynamics and clinical implications of prosthetic MR
are similar to that of native valve regurgitation, with
the clinical course depending on the severity and
chronicity of the MR, as well as the underlying etiol-
ogy that led to its development. Hemolytic anemia is
a well-recognized complication of mitral prosthetic
regurgitation, especially with mechanical valves, and
is commonly seen in mitral PVL.
TR, by contrast, results in elevated right atrial
pressure and progression to right heart failure with
venous engorgement, peripheral edema, ascites,
protein-losing enteropathy, cardiac cirrhosis, and
cardiac cachexia. The presence of residual TR in pa-
tients undergoing other valve interventions is
commonly associated with suboptimal outcomes (13).
Additionally, patients who develop progressive TR
late after left-sided valve surgery represent a partic-
ular challenge (14). In this subgroup, despite medical
management, surgical correction is associated with a
higher risk of morbidity and mortality as a result of the
presence of variable degrees of RV dysfunction, pul-
monary vascular disease, and right heart failure. The
pre-operative condition of the RV and the severity of
secondary renal and hepatic impairment are pre-
dictors of survival.
IMAGING OF VALVULAR REGURGITATION
Echocardiography is the gold-standard imaging mo-
dality for the evaluation of regurgitant valvular and
PVL lesions (15,16). Severity is assessed on the basis of
qualitative and quantitative measures. Qualitative
measurements include the area of regurgitant color
ﬂow, the density and contour of the regurgitant
signal, and other indexes such as the time velocity
CENTRAL ILLUSTRATION Flowchart of Transcatheter Therapeutic Options for the Treatment of Outﬂow and
Inﬂow Valves
Therapies for aortic regurgitation with...
...native valves
• No approved options for repair
• Transcatheter aortic valve replacement (TAVR): 
Jena-Valve and off-label TAVR
...mechanical prosthetic valves
• No approved options for repair or replacement
...biological prosthetic valves
• Valve-in-valve (ViV) off-label TAVR 
...paravalvular leaks (PVL) 
• Off-label Amplatzer vascular plug IV (AVP IV)
Therapies for pulmonic regurgitation with...
...native valves
• No approved options for repair
• Off-label transcatheter pulmonic valve replacement (TPVR):
Medtronic Melody valve and Edwards SAPIEN pulmonic 
transcatheter heart valve
...implanted conduits or biological prosthetic valves
• TPVR
...paravalvular leaks (PVL) 
• Off-label Amplatzer vascular plugs
Therapies for mitral regurgitation with...
...native valves
• Edge-to-edge repair: Mitraclip 
• Annuloplasty rings: Carillon (Direct); Mitralign, 
Accucinch device and Cardioband (Indirect)
• Chordal implants: NeoChord and V-Chordal
• Transcatheter mitral valve replacement (TMVR): CardiAQ mitral valve, 
Fortis mitral valve, TIARA mitral valve and Tendyne mitral valve
...mechanical prosthetic valves
• No approved options for repair or replacement
...biological prosthetic valves
• ViV off-label TAVR for prosthesis  
• Valve-in-ring (ViR) off-label TAVR for annuloplasty 
...paravalvular leaks (PVL)
• Off-label Amplatzer vascular plugs
Therapies for tricuspid regurgitation with...
...native valves
• Repair: Mitralign and TricCinch system
• Transcatheter tricuspid valve replacement (TTVR) concepts:
Heterotopic balloon or self-expanding implants and 
custom-made stent valves
...mechanical prosthetic valves
• No approved options for repair or replacement
...biological prosthetic valves and annuloplasty rings
• Off-label TAVR
...paravalvular leaks (PVL)
• Off-label Amplatzer vascular plugs
Ruiz, C.E. et al. J Am Coll Cardiol. 2015; 66(2):169–83.
Flowchart of novel transcatheter therapeutic options for the treatment of regurgitant native and prosthetic cardiac valves in the outﬂow
(aortic and pulmonic) and outﬂow (mitral and tricuspid) positions.
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172index; quantitative measurements include the diam-
eter of vena contracta, effective regurgitant oriﬁce
area, regurgitant volume, and regurgitant fraction
(16–18). Assessment of ventricular function including
ejection fraction, fractional area change, ventricular
2-dimensional strain/speckle tracking, and tricuspid
annular plane systolic excursion can also be obtained.
In transthoracic echocardiography, the position of
the interrogated valve plays an important part in the
accuracy of evaluation. The farther the distance of
the valve from the anterior chest wall, the higher
the likelihood of underestimating the severity of
regurgitation. Furthermore, the presence of a pros-
thetic valve may cause a shadowing artifact, making
assessment a challenge. Transesophageal echocardi-
ography (TEE) can solve some of these limitations.
Advancements in real-time 3-dimensional echocar-
diography provide superb visualization of cardiac
abnormalities, as well as wires, catheters, and
devices; it also provides real-time assessment for
any complications such as perforations, pericardial
tamponade, and device embolization.
Quantiﬁcation methods used in assessment of the
severity of prosthetic regurgitation are similar to
those used for native valve regurgitation; however, a
few caveats exist. Differentiation between trans-
valvular and paravalvular regurgitation can be chal-
lenging, as the origin of the jet may sometimes be
masked. For similar reasons, vena contracta may be
difﬁcult to accurately measure, particularly with
eccentric paravalvular jets. The circumferential
extent of the PVL, obtained by careful analysis of
color Doppler data from different views, can be used
as a semiquantitative assessment of PVL severity.
When all parameters ﬁt into 1 category, severity of the
regurgitation (native, prosthetic, or paravalvular) can
be determined. When a discrepancy exists, combining
all available data with data obtained by other imaging
modalities is of paramount importance for accurate
diagnosis (18).
Computed tomography angiography (CTA) en-
ables the evaluation of both cardiac structure and
function, and more recently, has been integral for
the characterization of both native and prosthetic
cardiac valves in the pre-procedural planning and
guidance of transcatheter valve therapies (19). CTA
can provide detailed analysis of valvular, para-
valvular, ventricular, and vascular anatomy. Direct
planimetry of the regurgitant oriﬁce area can be
performed with good correlation to regurgitant
severity by TEE (20). In addition, quantiﬁcation of
regurgitant fraction and volume on the basis of left
and right stroke volumes can be performed with
high correlation to transthoracic echocardiographyseverity (21). Functional evaluation of mechanical
valves and detection of pannus, prosthetic leaﬂet
thickening, thrombus adherence and/or calciﬁca-
tion, abnormal leaﬂet mobility, and the presence of
surrounding pseudoaneurysm or PVL(s) is also
possible (22). This information may help to deter-
mine the cause of regurgitation and to differentiate
transvalvular from paravalvular types in patients
with prosthetic valves.
Moreover, CTA can be employed to determine PVL
size and shape, course of tract, degree of calciﬁcation,
interaction with other cardiac structures, and best
access for transcatheter repair. Evaluation of pros-
theses in the aortic position is a challenge, as both
echocardiography and CTA may have signiﬁcant lim-
itations as a result of acoustic shadowing and atten-
uation artifacts. Fluoroscopy and angiography are
essential diagnostic modalities. Aortic root angio-
grams with selective contrast injections in varying
ﬂuoroscopic projections may help to differentiate
ﬂow across the center of the valve prosthesis (trans-
valvular) from ﬂow around the valve prosthesis (PVL)
and, with hemodynamics, aide in assessment of
severity.
Furthermore, cardiac magnetic resonance (CMR)
allows for assessment of valvular morphology,
quantitative volumes, and cardiac function without
the need for optimal acoustic windows. CMR appears
safe with most bioprosthetic valves; however, it is
generally less useful for mechanical prostheses
because of signiﬁcant local mechanical artifacts. In
patients who have transcatheter heart valves (THVs),
CMR may have a more signiﬁcant role. Echocardiog-
raphy often misclassiﬁes the severity of PVL after
TAVR, and in suspected cases, CMR may provide
more accurate quantiﬁcation of severity (23,24). In
patients with right-sided valve dysfunction, CMR is
considered the gold standard for measuring RV vol-
ume, an important parameter for determining the
optimal timing of intervention in chronic PR (25).
Nonetheless, each imaging modality described
provides its own unique detailed anatomic informa-
tion and spatial relationships of cardiac structures for
transcatheter therapies. However, each modality has
its own inherent practical limitations, which are sec-
ondary to its physical properties and further affected
by the underlying nature of the organs and tissues. It is
practically impossible for a single imaging modality to
capture all necessary details that would ensure clinical
accuracy and robustness of analysis while simulta-
neously being useful for guiding interventions. The
obvious approach is to integrate images from multiple
modalities to make a more reliable and accurate
assessment. Fusion imaging combines the relevant
FIGURE 1 Application of Multimodality Fusion Imaging Technology for the Planning and Guidance of
Transcatheter Heart Valve Implantation
(A) TEE-ﬂuoroscopy and (B) CTA-ﬂuoroscopy (EchoNavigator and HeartNavigator, Philips Healthcare, Best, the Netherlands) fusion imaging.
CTA ¼ computed tomography angiography; TEE ¼ transesophageal echocardiography.
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FIGURE 2 Current Transcatheter Technologies Available for the Treatment of
Regurgitant Lesions in Native and Prosthetic Outﬂow Valves
TAVR ¼ transcatheter aortic valve replacement; TPVR ¼ transcatheter pulmonary valve
replacement; ViV ¼ valve-in-valve.
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174information from 2 or more imaging sources into a
single image display, after appropriate coregistration
of each imaging dataset has been obtained.
To date, image registration and the fusion of rele-
vant features have been successfully performed with
CTA-ﬂuoroscopy and TEE-ﬂuoroscopy (26,27). Fusion
imaging provides improved spatial information, and
allows precise localization of abnormalities through
incorporation of 3-dimensional data while preserving
the temporal resolution of ﬂuoroscopy (Figure 1). This
ability to provide real-time imaging guidance in the
cardiac catheterization laboratory has the potential to
improve accuracy and safety while reducing radiation
exposure, contrast volume, and procedural time.
Fusion guidance has been utilized for directed
transcatheter access, as well as for procedural in-
terventions in the treatment of both valvular and
paravalvular regurgitation (28–31).
TRANSCATHETER THERAPIES FOR AR
NATIVE VALVES. Currently, there are no approved
THVs for the treatment of native valve AR in theUnited States. TAVR is an established treatment for
calciﬁc trileaﬂet aortic stenosis, where leaﬂet and/or
annular calciﬁcation aids in anchoring the THV. Pri-
mary AR often lacks this calciﬁcation; in its absence,
valve ﬁxation is a challenge, particularly when the
aortic annulus is dilated (32,33). THVs have been used
off-label in selected high-risk or extreme-risk AR
patients, preferably with the self-expanding types
(Figure 2). Prostheses are typically oversized relative
to the annulus to maximize radial strength and opti-
mize anchoring (34,35). To date, the largest multi-
center registry of 42 patients implanted with
the Medtronic CoreValve (Medtronic, Minneapolis,
Minnesota) showed a Valvular Associate Research
Consortium (VARC)-deﬁned success of 74.4%, with
comparable rates of stroke, vascular complications,
bleeding, and mortality to TAVR in aortic stenosis.
Residual PVL $þ2 and the need for valve-in-valve
(ViV) implantation were 21% and 19%, respectively,
demonstrating early feasibility of this thera-
peutic application in the context of procedural com-
plexities (36).
The Jena-Valve THV (JenaValve Technology,Munich,
Germany) is a second-generation, transapical TAVR
valve that has obtained regulatory approval to treat
patients with primary AR in native tricuspid aortic
valves (Figure 2). Its unique design, with active clip
ﬁxation of the aortic leaﬂets, allows for secure im-
plantation, even in the absence of calciﬁcation (37).
Hemodynamic and clinical outcomes are promising,
without any major adverse events. Early experience
for treatment of AR revealed 97% VARC-deﬁned
success, with all patients having # mild residual
PVL (37).
Other novel devices being evaluated for AR include
the Engager THV (Medtronic), the ACURATE THV
(Symetis SA, Ecublens, Switzerland), and the Helio-
Dock (Edwards Lifesciences, Irvine, California) (38,39)
(Figure 2). The Engager THV is a transapically deliv-
ered, self-expanding valve (like the Jena-Valve),
which has control arms designed to be placed into
the aortic sinuses and secure the aortic leaﬂets (40).
Similarly, the ACURATE THV is a transapically
delivered, self-expanding valve; however, it consists
of upper and lower crowns that enable valve ﬁxation
in a subcoronary and supra-annular position (41).
This unique implantation method does not clip, but
rather generates a waist for the leaﬂets, facilitating
device self-positioning and anchoring. The Helio-
Dock is a self-expandable, cloth-covered, nitinol
frame that is delivered transfemorally and engages
the aortic leaﬂets, embedding itself deeply within the
3 aortic sinuses. Transapical placement of a SAPIEN
XT (Edwards Lifesciences) is subsequently deployed
FIGURE 3 Current Transcatheter Technologies Used Off-Label for the
Treatment of PVLs
PVL ¼ paravalvular leak; TMVR ¼ transcatheter mitral valve replacement; ViV ¼ valve-
in-valve.
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175across the annulus, utilizing the superelastic dock to
increase friction and secure the THV (Figure 2).
Additional procedural considerations need to be
taken into account when applying transcatheter
therapies to native AR. Unlike TAVR with the absence
of aortic root calciﬁcation, there is a lack of ﬂuoro-
scopic landmarks for the aortic annulus, making
aortography, TEE, and fusion imaging even more
important during implantation. Rapid ventricular
pacing helps to stabilize THV positioning during
deployment, as cardiac motion is hyperdynamic and
ﬂow is increased during AR.
PROSTHETIC VALVES. More common, and recently
achieving U.S. Food and Drug Administration
approval, is the use of ViV in patients with degen-
erated bioprosthesis. Virtually all commercially
available valves have been used in this context
(Figure 2) (42). The presence of a previously implan-
ted prosthesis provides an ideal landing platform for
THVs. ViV is generally easier in patients with stented
(as compared with stentless) bioprostheses, and suc-
cessful implantation has been performed in patients
with degenerated homografts (43–45). The VIVID (ViV
International Data) registry, the largest experience
presently published, includes 459 patients who un-
derwent ViV implantation (30% AR alone, 30% com-
bination) with more self-expanding THVs used for
regurgitant failure (42). Procedural success was re-
ported to be as high as 93%, with 1-year survival
of 83%, and improved outcomes with primary pros-
thetic AR (46). The incidence of patient–prosthesis
mismatch appeared lower in patients with predomi-
nant AR at baseline (19% vs. 36%; p < 0.001). It is
important to note that there are currently no pub-
lished data on the mechanical interaction of surgical
valves with THVs and the long-term behavior of
ViV implants (47). ViV implants have also been used
to treat degenerated or malpositioned TAVR pros-
theses (48,49).
PVL IN SURGICAL AORTIC VALVES. For surgical
PVLs, surgery has been the traditional approach, and
involves either repair or re-replacement. This de-
pends on the surgical ﬁndings related to the etiology,
condition of the native annulus, size and location of
the leak(s), and surgical exposure. Failure rates range
from 12% to 35%, with mortality rates that increase
with reintervention; because the underlying patho-
logical process remains unchanged, recurrence is
common (50). TAVR patients are typically of high
surgical risk, and avoidance of open surgery is
important. Transcatheter approaches to surgical PVL
closure have been applied since 1992 with good
results and, more recently, to PVL after TAVR (51,52).Aortic bioprosthetic or mechanical PVLs are typi-
cally approached by a retrograde technique (53). Most
aortic leaks require a single device for closure,
although more can be placed, if necessary. Care must
be taken not to allow for device overhanging, as this
can potentially lead to obstruction of the coronary
ostia, alter valvular ﬂow in the setting of a narrow
LV outﬂow tracts, or cause prosthetic dysfunction,
particularly with mechanical prostheses. The most
commonly used devices are Amplatzer vascular plugs
(St. Jude Medical, St. Paul, Minnesota) off-label,
although any appropriately shaped Amplatzer family
of occluders has been used (Figure 3). Imaging
assessment of leak reduction is performed at all times
during the procedure, and once the operator is satis-
ﬁed with both reduction in degree of leak to mild
(or less, if possible) and normal leaﬂet function
(particularly for a mechanical valve), the devices are
released.
In a recent meta-analysis that included 12 clinical
studies and totaled 362 patients, overall technical and
procedural success rates were 86.5% and 76.5%,
respectively (54). Thirty percent of PVLs were in the
Ruiz et al. J A C C V O L . 6 6 , N O . 2 , 2 0 1 5
Catheter Therapies for Valvular Regurgitation J U L Y 1 4 , 2 0 1 5 : 1 6 9 – 8 3
176aortic position, with associated technical and proce-
dural success rates of 86.9% and 84.1%, respectively.
Successful closure was associated with a lower car-
diac mortality (odds ratio [OR]: 0.08; 95% conﬁdence
interval [CI]: 0.01 to 0.90), signiﬁcant improvement
in congestive heart failure or hemolysis (OR: 9.95;
95% CI: 2.1 to 66.7), and fewer repeat surgeries (OR:
0.08; 95% CI: 0.01 to 0.4) compared with failed
interventions.
PVL IN TRANSCATHETER AORTIC VALVES. Treat-
ment options for TAVR PVLs are focused on the
timing of onset and can be divided into acute and
chronic (55). When moderate or severe PVL is diag-
nosed acutely at the time of valve implantation,
therapeutic steps may include post-dilation to a
larger diameter or ViV implantation. If valve malpo-
sition or underexpansion is suspected, repeat balloon
dilation or implantation of a second valve lower in the
LV outﬂow tract may be considered (56). Redilation
is required in approximately 10% of cases, and a
second valve is required in 5%, when using a balloon-
expandable prosthesis (57,58).
In the chronic setting, when moderate or severe
PVL is conﬁrmed, strict attention to afterload reduc-
tion and diuresis is critical, particularly because the
LV is noncompliant as a result of years of aortic
stenosis. If further therapeutic intervention is indi-
cated, then percutaneous retrograde cannulation of
the defect with subsequent implantation of closure
devices is technically feasible and has been demon-
strated to be effective in a small case series (59).
Retrograde crossing may be quite challenging
because of the presence of native valve leaﬂets and
calciﬁcation. No single ideal plug has been identiﬁed,
although the Amplatzer Vascular Plug IV off-label is
preferred for post-TAVR leak closure because of its
smaller proﬁle and suitability for delivery via a stan-
dard diagnostic catheter (52). Care must be taken to
not disrupt TAVR valve position, particularly in a high
implant. Next-generation valves, such as the Edwards
SAPIEN 3 THV, are associated with a markedly lower
incidence of PVL (60). The self-expanding Lotus THV
(Boston Scientiﬁc, Natick, Massachusetts), which is
recapturable and repositionable, similarly has an
adaptive seal to allow optimal closure of the para-
valvular space (61).
TRANSCATHETER THERAPIES FOR PR
NATIVE AND PROSTHETIC VALVES. Timing of
intervention is based on symptomatology, RV vol-
ume, and function (62,63). Transcatheter pulmonary
valve replacement (TPVR) is designed for treatment
of circumferential right ventricular outﬂow tract(RVOT) conduit dysfunction when there is evidence
of signiﬁcant pulmonary stenosis and/or regurgita-
tion. TPVR provides an additional therapeutic option,
thereby extending conduit lifespan and avoiding the
need for repeat median sternotomy (Figure 2) (64,65).
The Melody THV (Medtronic) was the ﬁrst to receive
approval. A second TPVR option is now available: the
SAPIEN pulmonic THV (Edwards Lifesciences)
received the CE mark in 2010 and is currently under
investigation in the United States (65,66).
Short-term and medium-term outcomes of the
Melody valve worldwide suggest signiﬁcant hemo-
dynamic and clinical improvements, with good
durability (67–69). Improvements in RV end-diastolic
volume have been demonstrated, and the impact of
longer-term remodeling on functional status is being
evaluated (70). To date, TPVR in patients affected by
isolated PR has demonstrated less rewarding symp-
tomatic, hemodynamic, and functional improvement
than that affected by RVOT obstruction with or
without associated PR (71). The U.S. IDE (Investiga-
tional Device Exemption) and Post-Approval Study
trials revealed a >90% 1-year freedom from reinter-
vention or valvular dysfunction. Any evidence of
dysfunction should prompt a thorough investigation
for stent fracture or endocarditis (72,73). Stent frac-
ture is the primary cause for reintervention, because
of close apposition of the RVOT to the sternum, with
excessive loading forces and the intrinsic character-
istics of balloon-expandable stent metals (74). Pre-
stenting of the landing zone before Melody THV
placement has signiﬁcantly reduced stent fracture
rates (72,73).
There remains a subset of patients with native
RVOT anatomy or a transannular patch yet to undergo
surgical RV-to-PA conduit or bioprosthetic valve
placement where TPVR is desired. The goal is to
provide a THV that will reduce RVOT size while
incorporating a pulmonary valve, or to better conform
to an irregular, noncircumferential RVOT (potentially
utilizing hybrid, off-pump, surgical collaboration
for RVOT reduction) (75). Expansion of sizes/types
of TPVR valves will facilitate broader applications
to a growing population of both young and older
patients with RVOT dysfunction (65,75–77). Off-label
use of the Melody or SAPIEN XT THV has been
reported in native RVOTs with appropriate anatomy,
noncircumferential RVOT conduits, and bioprosthetic
valve failure in the right-sided and, more recently,
in the left-sided positions (76). Additionally, the
newly designed Venus-P valve (Venus Medtech,
Shanghai, China) has been implanted ﬁrst-in-man
(FIM) in the native RVOT with a good result
(Figure 2) (78).
FIGURE 4 Current Transcatheter Technologies Available for the Treatment of
Regurgitant Lesions in Native and Prosthetic Inﬂow Valves
ADO ¼ Amplatzer Ductal Occluder; AVP ¼ Amplatzer Vascular Plug; mVSD ¼ Amplatzer
muscular VSD occluder.
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177PVL IN SURGICAL OR TRANSCATHETER PULMONIC
VALVES. PVL in surgical prostheses or following
TPVR is very uncommon and typically less clinically
important. A rare report of transcatheter pulmonary
PVL closure has been reported (79). If needed, a
standard right heart approach is undertaken, either
via the right internal jugular or femoral veins, with
techniques similar to aortic or mitral PVL closure.
Unlike left-sided PVLs, there is an inability to create
an arteriovenous loop to provide support for sheath
delivery; stable wire position in the distal PA is
essential.
TRANSCATHETER THERAPIES FOR MR
NATIVE VALVES. Most transcatheter therapies for
the mitral valve have been developed on the grounds
of an established surgical procedure. MitraClip
(Abbott Vascular, Menlo Park, California) (Figure 4) is
the most adopted technology, utilized in nearly
20,000 high-risk or inoperable patients worldwide.
The device consists of a cobalt-chromium clip that
reproduces the Alﬁeri repair, a surgical technique in
which opposing leaﬂets at the site of MR are sutured
(80). A transseptally delivered, multisteering catheter
is directed toward the mitral valve; the clip is then
opened and oriented perpendicular to the coaptation
line in order to grasp the free edges of the opposing
leaﬂets, creating a double-oriﬁce mitral valve. It is
repositionable and retrievable, and multiple clips can
be deployed to achieve optimal results. In the
EVEREST study (Endovascular Valve Edge-to-edge
REpair STudy), the MitraClip had a superior safety
proﬁle when compared with surgical repair, mostly
on the basis of a lower risk of transfusions (81).
In recent registries, procedural success has largely
increased, with a decrease in residual MR, improve-
ment of New York Heart Association functional class,
and improved quality of life indicators (82,83).
Satisfactory outcomes have been reported when
used in patients with advanced heart failure, non-
responders to cardiac resynchronization therapy, and
in combination with TAVR (84,85). MitraClip therapy
has also been successfully adopted following surgical
mitral valve repair, including in patients with ring
annuloplasty and/or leaﬂet repair and in patients who
developed late systolic anterior motion with LV
outﬂow tract obstruction (86,87). As with any ther-
apy, appropriate patient selection is crucial; leaﬂet
disruption or calciﬁcation at the site of MR, poor
leaﬂet mobility, small oriﬁce area, and multiple jets
are the main factors causing suboptimal outcomes. In
those requiring surgery, the surgery occurred within
6 months after implantation and surgical options arepreserved, with 84% able to undergo successful sur-
gical repair (88). Another device that improves leaﬂet
coaptation is the Mitra-Spacer (Cardiosolutions,
Stoughton, Massachusetts), a polymer spacer that
positions itself at the coaptation zone, ﬁlling the
regurgitant oriﬁce and providing a sealing surface for
the leaﬂets. Anchored to the LV apex, the device can
be delivered via a transseptal or transapical approach.
It does not alter the mitral apparatus and can be fully
removed; potential complications include thrombus
formation or iatrogenic mitral stenosis.
Indirect annuloplasty utilizes the coronary sinus to
reshape the mitral annulus. Its close proximity allows
for device placement that will shorten the posterior
annulus, decreasing the septal-lateral dimension. As
a result of suboptimal and unpredictable efﬁcacy, and
the risk of coronary obstruction and device perfora-
tion, initial outcomes have not been satisfactory
(89,90). The Carillon Mitral Contour System (Cardiac
Dimensions, Kirkland, Washington) (Figure 4), 2
self-expanding nitinol anchors connected by a ﬁxed-
length, tension-adjustable cable recently achieved
the CE mark (91). The TITAN (Transcatheter Implan-
tation of Carillon Mitral Annuloplasty Device) trial
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with functional MR (92). The implanted cohort
demonstrated signiﬁcant reductions in MR and a
corresponding reduction in LV diastolic and systolic
volumes. Beyond coronary sinus annuloplasty,
other indirect annuloplasty approaches have been
attempted to reshape/remodel the annulus, including
external compression of the atrioventricular groove,
the implantation of cinching devices, and application
of radiofrequency or ultrasound energy to shrink
annular collagen (93–96). Many of these technologies
have already been abandoned because of their lack of
efﬁcacy and/or safety.
By contrast, direct annuloplasty is the most prom-
ising approach for transcatheter repair because it
closely reproduces the gold-standard surgical tech-
nique. The Mitralign system (Mitralign, Tewksbury,
Massachusetts) (Figure 4) has been designed to
perform selective plications in the posterior annulus
by deploying couples of transannular pledgeted an-
chors. Tension is applied to sutures connecting the
anchors to decrease posterior annular size. Patient
enrollment in the CE mark trial is completed, but the
device is still not available. The Accucinch system
(Guided Delivery Systems, Santa Clara, California)
(Figure 4) utilizes a similar technique by implanting a
series of 12 retrievable anchors in the subannular
space, extending from trigone to trigone. Enrollment
into the CINCH2 safety and feasibility trial is
underway. The Cardioband system (Valtech Cardio,
Or-Yehuda, Israel) (Figure 4) is the closest trans-
catheter device to a surgical ring (97). It is delivered
from a transseptal approach, and a Dacron band is
implanted from trigone to trigone using multiple
annular anchors. The anchors are delivered under
echocardiographic and ﬂuoroscopic guidance, starting
from the anterolateral and progressing to the poster-
omedial commissure. Early clinical experience is pro-
mising (97,98). However, the major limitation of these
devices is that they are partial rings. Currently, place-
ment of a complete mitral annuloplasty ring is being
evaluated using the Millipede (Millipede, Ann Arbor,
Michigan) and enCor (Valcare, Irvine, California)
systems (Figure 4). Both are delivered via a transseptal
approach and ﬁxed into the periannular space.
Lastly, chordal implants are synthetic sutures
that can be used to correct leaﬂet prolapse, usually
as a result of ruptured or torn chordae. Implants
are attached to the free leaﬂet margins and
anchored to the papillary muscles or LV myocardium.
The NeoChord system (NeoChord, Eden Prairie,
Minnesota) (Figure 4) allows for open surgical trans-
apical deployment (99). The TACT (Transapical Arti-
ﬁcial Chordae Tendinae) trial enrolled 30 patientswith severe, isolated posterior leaﬂet prolapse who
underwent placement of at least 1 artiﬁcial NeoChord.
Procedural success was noted in 87% of patients, with
65% achieving MR reduction to #2þ at 30 days.
NeoChord has achieved the CE mark. V-Chordal
(Valtech Cardio) (Figure 4), originally designed for an
off-pump transatrial approach, allows for chordal
implantation, with the ability to adjust chordal length
under physiological conditions to optimize leaﬂet
coaptation. The FIM trial of 7 patients revealed com-
plete procedural success with efﬁcacy at 2 years. The
newer transseptal system has a cinching device that
secures 2 chords for each implant. Pre-clinical trials
are underway.
Adding to developments in valve repair, trans-
catheter mitral valve replacement (TMVR) is rapidly
evolving. Unlike the aortic valve and TAVR, the com-
plexities of the mitral apparatus make TMVR a chal-
lenge. Concerns include the larger annular sizes and
asymmetrical anatomy, the need for valve anchoring,
and the potential for developing LV outﬂow tract
obstruction and PVL; durability issues dealing with
stent fracture, tissue erosion and degeneration require
evaluation. Novel valve designs such as a D-shaped
frame/oriﬁce, atrial skirt, self-expanding frame, and
active ﬁxation systems focus on these issues. None-
theless, TMVR is still in its infancy, with limited
FIM experience (100–103). Four devices have been
tested in early clinical trials, the CardiAQ (CardiAQ
Valve Technologies, Irvine, California), Fortis
(Edwards Lifesciences), TIARA (Neovasc, Vancouver,
British Columbia, Canada), and the Tendyne (Tendyne
Holdings, Roseville, Minnesota) THVs (Figure 4),
but with suboptimal outcomes, highlighting the
steep learning curve and the importance of patient
selection.
PROSTHETIC VALVES. Although transcatheter mitral
technologies remain in early clinical stages, current
THVs are being implanted successfully within surgical
mitral platforms, such as degenerative bioprostheses
and complete annuloplasty rings (valve-in-ring [ViR]).
The SAPIEN XT (Edwards Lifesciences) and Melody
(Medtronic) THVs are currently utilized off-label in
the mitral position (104–107). Data from the VIVID
registry for mitral ViV/ViR will soon elucidate the
efﬁcacy and safety of this technique. To date, the
results of 7 Melody ViV implantations within a
high-pressure, left-sided hemodynamic environment
(1 mitral, 6 aortic) revealed complete freedom from
regurgitation and an 86% freedom from signiﬁcant
stenosis at 1-year follow-up (99). The majority of
implantations are performed using a surgical trans-
apical approach. Proper patient screening and device
selection are crucial for success, with a reduction in
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obstruction.
PVL IN SURGICAL MITRAL VALVES. Mitral bio-
prosthetic and mechanical PVLs are typically
approached using an antegrade cannulation tech-
nique through transseptal puncture. Access to the
mitral valve can be a challenge, especially for poste-
riorly and medially located PVLs as a result of unfa-
vorable angulation, and in the presence of mechanical
aortic valves. Transapical access (TA) can facilitate
more precise and accurate navigation within the LV,
and ultimately can lead to a decrease in ﬂuoroscopy
and procedural times for mitral PVL closure of nearly
35% (26). TA mitral PVL closure can be performed
through either an open surgical hybrid or a percuta-
neous approach, and with high procedural success
rates (26,108–110). Given previous cardiac surgery
that requires pericardiotomy in this patient popula-
tion, transcatheter techniques with safe closure
can be achieved using off-label Amplatzer devices
(St. Jude Medical) (Figure 3). Furthermore, with the
use of CTA-ﬂuoroscopy fusion imaging, percutaneous
TA puncture can be achieved with an accuracy of
within 5 mm of the intended entry site and approxi-
mately 15 mm away from the left anterior descending
artery (28). The transapical retrograde approach has
increasing utility and is the preferred approach at
some centers, especially in the presence of double
mechanical prosthetic valves.
Like aortic PVL closure, the Amplatzer family of
occluders (St. Jude Medical), are utilized off-label to
close the defect. One must pay attention so as not
to impinge on the prosthetic valve leaﬂets, and mul-
tiple smaller devices may be required to better
conform to the paravalvular space. In the same meta-
analysis of 12 clinical studies totaling 362 patients
described earlier, 70% of PVLs were in the mitral
position, with technical and procedural success rates
of 82.3% and 73.3%, respectively (54). Twelve percent
of the closures were performed using a transapical
approach, with a reported success rate of 100%,
compared with success rates of 78.4% with an ante-
grade transseptal approach, and 66.4% with a retro-
grade transaortic approach.
Mitral annuloplasty ring failure may occur with
evidence of signiﬁcant para-annular ring regurgita-
tion (PAR). PAR can be divided into 2 types: partial
dehiscence of the prosthetic ring from the mitral
annulus, and tearing of mitral annular tissue without
ring dehiscence (111). Little is known about percuta-
neous options for mitral PAR closure and its resultant
complications. Single case reports have identiﬁed the
potential utility of transcatheter closure with anAmplatzer device for leaks from partial dehiscence,
and ViR implantation for leaks from tearing using a
Melody THV (Medtronic) with a novel, neochordal
tethering approach to the transapical access site
(106,107). The longer covered valved stent allows the
native leaﬂets to seal over the stent during systole.
This approach provides proof-of-concept that ap-
propriate sealing can occur at the leaﬂet level
without annular apposition, potentially suggesting a
future role of transcatheter mitral valve replacement
technologies.
PVL IN TRANSCATHETER MITRAL VALVES. The high
rates of moderate or severe PVL associated with
TAVR compared with surgical prostheses and its
impact on clinical outcomes pose concerns for TMVR
(112). Given the complex nature of the mitral appa-
ratus, PVL may be more common than with TAVR
and lead to higher rates of hemolysis, making TAVR
less well tolerated. Novel valve designs have been
developed, including an atrial skirt and/or D-shaped
structure to better conform to the native saddle-
shaped annulus, with a focus on reducing PVLs.
FIM implantations of TMVR are promising, but it is
too early to elucidate the potential scope of this
problem (100–103).
TRANSCATHETER THERAPIES FOR TR
NATIVE AND PROSTHETIC VALVES. Surgical treat-
ment of functional TR has been largely focused on
annuloplasty with speciﬁcally designed right-sided
devices; repair or replacement (with or without
chordal or papillary reconstruction) is performed less
frequently and most often involves patients with
congenital heart disease, organic lesions, or advanced
annular dilation. When the anatomy is appropriate,
transcatheter therapy may be an attractive alternative
to surgery for patients deemed high risk. Limited data
are available about the feasibility and efﬁcacy of
percutaneous tricuspid valve therapies. The use of
the MitraClip from a transjugular approach has been
reported in 1 patient with corrected transposition of
the great arteries and a left-sided, anatomically
tricuspid mitral valve (74). The trileaﬂet design,
higher chordal density, and wide malcoaptation gaps
from annular dilation make MitraClip an uncertain
solution for native functional and congenital TR.
Two other devices have been successfully implan-
ted FIM to treat the valvular components of func-
tional TR. The Mitralign device (Figure 4), originally
designed to remodel the mitral annulus, has been
successfully implanted in 2 patients for severe TR,
with slight modiﬁcations of the delivery system (113).
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phragmatic) annulus, replicating the bicuspidization
Kay procedure. In-hospital results were favorable,
with dramatic reductions in right atrial pressure and
annular area, and improvement in LV stroke volume.
The TriCinch System (4TECH Cardio, Galway, Ireland)
(Figure 4) is a percutaneous device designed to cinch
the anteroposterior dimension of the annulus in
order to improve coaptation (annular cinching). The
delivery system allows transfemoral ﬁxation of a
stainless-steel corkscrew into the anteroposterior TV
annulus, which is connected through a Dacron band
to a self-expanding nitinol stent placed in the hepatic
region of the inferior vena cava. It has been implanted
in a limited number of patients with isolated func-
tional TR. In addition, the Millipede, currently in
pre-clinical trials, is a similar device for the mitral
position with a complete tricuspid ring and may offer
simpler device delivery.
Transcatheter tricuspid valve replacement has not
been performed to date, although several concepts
are in the pre-clinical phase. Heterotopic implanta-
tion of a balloon or self-expanding valve in the infe-
rior vena cava, cranial to the hepatic veins, has been
done in a limited number of end-stage patients,
aiming at reducing venous hypertension in the hep-
atorenal system. Likewise, the addition of a valve in
the superior vena cava would prevent transmission of
systolic waveforms of right atrial hypertension into
the superior central systemic venous system. How-
ever, with this approach, the right atrium undergoes a
potentially detrimental ventricularization process.
Some experience has accumulated with balloon-
expandable THV implantation in rings (ViR) or in
degenerated bioprostheses (ViV) in the tricuspid
position (114,115).
PVL IN SURGICAL TRICUSPID VALVE. Hemodynamically
signiﬁcant tricuspid PVL, like native tricuspid regur-
gitation, is rare relative to its occurrence with other
cardiac valves. Whether this is a result of few patientsreceiving tricuspid valve replacements, or technical
issues of implantation in this position remains
unclear. Limited data suggest that typical clinical
manifestations are severe hemolysis and hepatic
dysfunction. Recently, successful transcatheter clo-
sure has been reported with both bioprosthetic and
mechanical prostheses (116–119). Similar to pulmonic
PVL, access requires a right heart approach with sta-
ble wire positioning.
FUTURE DIRECTIONS
The future of transcatheter therapies for valvular
and paravalvular regurgitation is a matter of fusion—
of imaging, of device technologies, and of ope-
rator skillsets. The fusion of imaging offers novel
opportunities in the diagnosis, planning, and guid-
ance of interventions. Combining structural and
functional data is crucial for appropriate patient risk
stratiﬁcation and selection. The merging of multiple
imaging modalities can unify information for the
operator to aid in improving procedural efﬁcacy and
safety. Interdisciplinary collaboration and progres-
sion to less invasive techniques has enabled the
fusion of technologies, with a steady increase in
available hybrid therapies. Although most surgical
procedures will likely be performed percutane-
ously with dedicated devices, the knowledge and
experience gained from transcatheter interventions
may enhance current surgical tools; a steady trend
toward sutureless technologies is a clear example.
Moreover, a uniﬁed growth in shared technology is
inevitable. Finally, but most importantly, this evolu-
tion has inﬂuenced a new breed of operators and
fusion of multidisciplinary skillsets, all focused on
achieving optimal results for patients with VHD.
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